Ozempic Faces $2 Billion Lawsuit as Safety Concerns Grow

The popular weight-loss and diabetes drug Ozempic is at the center of a $2 billion lawsuit consolidating claims from approximately 1,800 users. Plaintiffs allege the medication caused severe vision loss, specifically non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition affecting blood flow to the optic nerve, and raises concerns about a potential connection to aggressive thyroid cancer. While the manufacturer denies wrongdoing, stating the drug is safe when prescribed and its benefits outweigh risks, the lawsuits highlight emerging data suggesting a higher risk of aggressive thyroid cancers than previously disclosed.

The legal battle has sparked a wider debate about the long-term risks of weight-loss drugs and the need for more transparent safety studies, especially as their use expands beyond diabetes treatment. Critics advocate for a greater emphasis on diet, lifestyle changes, and preventive care.

Medical professionals emphasize individualized treatment plans made in consultation with healthcare providers. The outcome of this case is expected to significantly influence the regulation, marketing, and prescription of weight-loss and metabolic drugs in the future.

(Source：Ghafla)